Biotech company Amgen laying off about 380 in R&D The dawning Sentinel Those drugs consider OncoVex, for malignant melanoma; two other oncology drugs, one for ovarian malignant tumor and the other for pancreatic cancer; and drugs for psoriasis and osteoporosis. "Amgen believes this restructuring effort is the befitting response ... and more » Link To Article
No comments:
Post a Comment